Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in JapanPRNewsWire • 08/24/22
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor MicroenvironmentPRNewsWire • 03/21/22
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone SymposiumPRNewsWire • 03/14/22
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple MyelomaPRNewsWire • 03/09/22
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of DirectorsPRNewsWire • 02/24/22
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022PRNewsWire • 02/10/22
Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT AntibodiesPRNewsWire • 01/18/22